SciELO - Scientific Electronic Library Online

 
vol.58 issue5Mesenchymal stem cell; history, biology and clinical application author indexsubject indexsearch form
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista de investigación clínica

On-line version ISSN 2564-8896Print version ISSN 0034-8376

Abstract

CASTILLEJOS-LOPEZ, Manuel de Jesús; GARCIA-SANCHO, Ma. Cecilia; TORRES-ESPINDOLA, Luz Ma.  and  PEREZ-PADILLA, José Rogelio. Contributions of pharmacogenomics to enhance the efficiency of randomized clinical trials. Rev. invest. clín. [online]. 2006, vol.58, n.5, pp.512-524. ISSN 2564-8896.

One of the greatest advances of the modern medicine has been the report of the complete sequence of the human genome. This has brought as a consequence an evolution in the design of the clinical research, in special of the randomized clinical trials (RCTs). The pharmacogenomics, a powerful tool for the prediction of pharmacological effects based on the genotype of the studied subjects, promises to be very useful next years for the development of the pharmaceutical industry. With the present integration of the pharmacogenomical methods to the investigation and development of new medicines it may start a new era in the medical prescription producing more individualized therapies, reduction of adverse events in the patients and in addition a faster development of new medicines in a more cost-effective way. Nevertheless new methodological, ethical and social challenges appear that will have to be solved simultaneously, to allow a legal use of the vast information generated by the genetic information.

Keywords : Randomized clinical trials; Efficacy; Pharmacogenomics; Genotyping; Polymorphisms.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License